Results 81 to 90 of about 11,212 (232)
Muscle &Nerve, Volume 73, Issue 6, Page 1016-1024, June 2026.ABSTRACT Introduction/Aims Myasthenia gravis (MG) is associated with thymic neoplasms. However, an increased prevalence of extrathymic neoplasms has also been reported. This study aimed to evaluate the rates of malignancy in MG patients while accounting for risk factors such as disease characteristics and immunomodulatory treatments.
Keshet Pardo +13 more
wiley +1 more source
An Atypical Case of Myasthenia Gravis: Purely Bulbar in a Young Male
McGill Journal of Medicine, 2020 Myasthenia Gravis (MG), an uncommon autoimmune syndrome caused by the failure of neuromuscular transmission, results from bind- ing of autoantibodies to proteins that are involved in signaling at the neuromuscular junction (1).
Muhammad Amer Saleem +3 more
doaj
Muscle &Nerve, Volume 73, Issue 6, Page 1065-1072, June 2026.ABSTRACT Introduction/Aims Thymectomy is associated with positive effects on myasthenia gravis (MG), but there is conflicting evidence regarding potential deleterious long‐term outcomes, such as increased cancer and autoimmune disease risk. We aimed to assess these outcomes in thymectomized versus non‐thymectomized MG patients.
Mohamed Khateb +3 more
wiley +1 more source
Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies
ChemBioChem, Volume 27, Issue 9, 14 May 2026.This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci +5 more
wiley +1 more source
Disfagia e disartria: forma invulgar de apresentação da Miastenia Gravis.
Acta Médica Portuguesa, 2008 Myasthenia Gravis is an autoimmune disorder that generally presents with ocular symptoms, specially diplopia and ptosis. Dysphagia may be a manifestation of the generalised type of the disease, but rarely is its presenting feature. The authors describe a
Sara Ferreira +5 more
doaj +1 more source
Annals of Clinical and Translational Neurology, Volume 13, Issue 5, Page 1028-1040, May 2026.ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Ocular sequelae from the illicit use of class A drugs [PDF]
, 2004 Aim: To highlight the changes that may take place in the visual system of the class A drug abuser. Methods: A literature review was carried out of ocular/visual sequelae of the more common class A drugs.
Firth, A.Y.
core
Sneddon's syndrome: clinical and laboratory analysis of 10 cases. [PDF]
, 2004 Sneddon's syndrome is characterized by livedo reticularis and cerebrovascular lesions. We report the cases of women (mean age, 36.2 +/- 8.1 years) diagnosed with Sneddon's syndrome based on the presence of livedo reticularis and characteristic ...
Akyol, Melih +5 more
core +1 more source
Treatment of Ocular Myasthenia Gravis
Asia-Pacific Journal of Ophthalmology, 2019 Myasthenia gravis is a relatively common neuromuscular disorder, with ocular myasthenia gravis being a subset defined as myasthenia gravis limited to the orbicularis, levator, and extraocular muscles. Patients with ocular myasthenia gravis can have disabling diplopia or functional blindness from ptosis and in most cases treatment is required.
openaire +2 more sources
Annals of Neurology, Volume 99, Issue 5, Page 1139-1151, May 2026.Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu +15 more
wiley +1 more source